Genmab A/S Virtual R&D Update and ASH Data Review Transcript - Thomson StreetEvents

Genmab A/S Virtual R&D Update and ASH Data Review Transcript

Genmab A/S Virtual R&D Update and ASH Data Review Transcript - Thomson StreetEvents
Genmab A/S Virtual R&D Update and ASH Data Review Transcript
Published Dec 11, 2024
21 pages (14824 words) — Published Dec 11, 2024
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of GMAB.CO corporate analyst meeting

  
Brief Excerpt:

...Hello and welcome to Genmab's 2024 R&D update and ASH data review. I'm Jan Van de Winkel, President and CEO of Genmab, and I'm delighted to share with you the highlights for Genmab in 2024 as well as data from this year's meeting. As always, we have a busy agenda, so let's jump right in. Next slide, please. As a reminder, this presentation may contain forward-looking statements and as such may contain certain risks and uncertainties. Let's move to slide 3 Genmab is a science anchor and innovation -- has a science-anchored and innovation-focused culture. Collaborations and partnerships have always been part of our DNA. During today's presentation, we will reference some of the products being developed under the strategic collaborations, and this slide acknowledges those relationships. Let's move to our agenda on slide 4. We will begin with a review of the progress we made this year as we advance toward our 2030 vision. Central to our achievements are the significant advancements for EPKINLY...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Genmab A/S
Ticker
GMAB.CO
Time
4:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Jonathan Chang. - LeeRink Partners - Analyst : Great. Thanks for taking my questions. First, maybe just to clarify is Dr. Lee available for the Q&A session. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. DECEMBER 11, 2024 / 4:00PM, GMAB.CO - Genmab A/S Virtual R&D Update and ASH Data Review

Question: Jonathan Chang. - LeeRink Partners - Analyst : Got it. So then maybe for the Genmab team, how are you thinking about potential opportunities for EPCO beyond DLBCL and follicular lymphoma? What do you need to see before advancing EPCO for CLL in later stage development? And also, what are the considerations for potential autoimmune disease applications? Thank you.

Question: Yaron Werber - Cowen - Analyst : Great. Thanks so much for the questions. I have a couple of questions. First of all, when the CLL data is really intriguing, we did a KOL event at ASH and they're definitely highlighting that as one of the highlights in CLL. When you're looking at the OP T1, you're reducing the CRS nicely, so you don't have Grade 3 anymore. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. DECEMBER 11, 2024 / 4:00PM, GMAB.CO - Genmab A/S Virtual R&D Update and ASH Data Review The CR rate was lower, though. It was 10%. Is that just a function of an early follow-up in that specific cohort or anything we should be thinking about? And then maybe just secondly, when we looked at the data in -- it was a data for the first-line follicular, the data is really compelling, but there was a lot of dropouts in that cohort. I think nine patients dropped because of -- because of COVID. Did that sort of happen later on? Or how should we think about tolerability?Thank you.

Question: Paul Jeng - Guggenheim Securities, LLC - Analyst : Hey, this is Paul on for Michael Schmidt from Guggenheim. Thanks for taking our question and, and thanks for the helpful call. For Dr. Hutchings, would be great to get your view on the recent data for talquetamab plus R2 and second line follicular, which showed, I think, around 20 months PFS. How does that sort of data impact the bar for EPCO and R2? And how do you and your peers plan to sequence -- assume both regimens might be approved in the setting? Thank you.

Question: Yifeng Liu - HSBC Bank Plc - Analyst : Thanks for taking my questions and I got acasunlimab. In 2025, there have been a data update for Phase II. Could you maybe share some color on what to expect in that update? And secondly, on its upcoming Phase III study? And I just wonder if there's any plans to test progression-free survival in the interim? Thanks. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. DECEMBER 11, 2024 / 4:00PM, GMAB.CO - Genmab A/S Virtual R&D Update and ASH Data Review

Table Of Contents

Genmab A/S Annual Shareholders Meeting Transcript – 2025-03-12 – US$ 54.00 – Edited Transcript of GMAB.CO shareholder or annual meeting 12-Mar-25 1:00pm GMT

Genmab A/S Corporate Call On HexaBody CD38 (GEN3014) Transcript – 2025-03-10 – US$ 54.00 – Edited Transcript of GMAB.CO conference call or presentation 10-Mar-25 4:00pm GMT

Genmab A/S at TD Cowen Healthcare Conference Transcript – 2025-03-03 – US$ 54.00 – Edited Transcript of GMAB.CO presentation 3-Mar-25 6:50pm GMT

Genmab A/S Q4 2024 Earnings Call Transcript – 2025-02-12 – US$ 54.00 – Edited Transcript of GMAB.CO earnings conference call or presentation 12-Feb-25 5:00pm GMT

Genmab A/S at JPMorgan Healthcare Conference Transcript – 2025-01-14 – US$ 54.00 – Edited Transcript of GMAB.CO presentation 14-Jan-25 11:00pm GMT

Genmab A/S at Citi Global Healthcare Conference Transcript – 2024-12-03 – US$ 54.00 – Edited Transcript of GMAB.CO presentation 3-Dec-24 7:30pm GMT

Genmab A/S Q3 2024 Earnings Call Transcript – 2024-11-06 – US$ 54.00 – Edited Transcript of GMAB.CO earnings conference call or presentation 6-Nov-24 5:00pm GMT

Genmab A/S at Morgan Stanley Global Healthcare Conference Transcript – 2024-09-04 – US$ 54.00 – Edited Transcript of GMAB.CO presentation 4-Sep-24 5:05pm GMT

Genmab A/S Q2 2024 Earnings Call Transcript – 2024-08-08 – US$ 54.00 – Edited Transcript of GMAB.CO earnings conference call or presentation 8-Aug-24 4:00pm GMT

Genmab A/S to Discuss Proposed Acquisition of Call Transcript – 2024-04-03 – US$ 54.00 – Edited Transcript of GMAB.CO M&A conference call or presentation 3-Apr-24 11:00am GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Genmab A/S Virtual R&D Update and ASH Data Review Transcript" Dec 11, 2024. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Genmab-A-S-Virtual-R-D-Update-and-ASH-Data-Review-T16172341>
  
APA:
Thomson StreetEvents. (2024). Genmab A/S Virtual R&D Update and ASH Data Review Transcript Dec 11, 2024. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Genmab-A-S-Virtual-R-D-Update-and-ASH-Data-Review-T16172341>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.